explore -WSS

explore

author：Wikipedia 2025-09-28 02:27:26 - browse：65296

Dr. Peter Bach — Peter Bach, shown at the 2019 STAT summit, is now chief medical officer of Delfi. Emilie Pickering for STAT

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening.

The approach represents a new one in the field of liquid biopsy, in which DNA fragments in blood are used to detect or learn about tumors. Grail, another company developing a blood test for cancer screening, has insisted that its product would be best used to detect multiple cancers at once. Other companies, including Exact Sciences and Freenome, are developing tests that would focus on detecting colorectal cancer. But Delfi appears to be the first to focus first on lung cancer, the leading cause of cancer death.

Delfi’s executives, in an interview with STAT, were clear that they view the initial launch as an opportunity to gather information, and not a real commercial coming out. The test will likely become available in limited ways with specific partners and will not initially be covered by insurance. Delfi declined to reveal a specific price, but said that its early access customers, which it is not yet disclosing, will be able to use FirstLook Lung for several hundred dollars. Such a rollout does not require approval from the Food and Drug Administration, which Delfi does not have.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： FTX founder Sam Bankman

WSS

Testing for cancer recurrence creates a new limbo for patients

Emergency medicine has repudiated 'excited delirium.' Now what?

Medtronic CEO on promising devices for diabetes, hypertension

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Choosing scientific sides in the fight against Alzheimer's

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

hotspot

explore

hotspot

How one medical school became remarkably diverse

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Psychedelics group wrestles with new pharma identity

In venture capital firm's success, lessons for turning crisis into profit

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Hospitals use virtual reality to design more inclusive rooms for kids

New air purifier tech could be key to improving indoor air quality

CDC launches VaccineFinder tool to locate Covid

The high cost of giving birth even with insurance

Hospitals warn Medicare's drug payment fix is ‘unlawful’

explore

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

FDA has safety concerns on CRISPR

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Sage's campaign to raise awareness of postpartum depression hits a nerve

Paying for Covid pills will soon shift to insurers

Maker of FluMist seeks to allow at

entertainment

focus

entertainment

entertainment